Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service
December 14 2020 - 8:00AM
via NewMediaWire – Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, and
Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company
focused on distributing comprehensive solutions for COVID-19
screening and diagnosis, and developing blood tests for early
detection of cancer and Alzheimer’s disease, today announced the
signing of a distribution agreement for AditxtScore™ for COVID-19,
with planned availability in January 2021.
Todos Medical has secured the rights to distribute AditxtScore™
for COVID-19 to monitor immunity against SARS-CoV-2. Blood samples
will be collected by Todos and/or its network of partners and sent
to Aditxt’s CLIA accredited AditxtScore™ Center for
processing.
Amro Albanna, Co-founder and CEO of Aditxt, commented, “This
agreement marks a milestone for AditxtScore™ and Aditxt as a whole.
Todos Medical is Aditxt’s first commercial customer for our
proprietary AditxtScore™ immune monitoring platform and its first
application, AditxtScore™ for COVID-19. As the availability of
COVID-19 vaccines increases, the need to understand an individual’s
immune profile to measure its effectiveness, increases as well. We
look forward to working with the team at Todos and providing our
innovative AditxtScore™ platform as a complement to the suite of
testing solutions that they offer.”
Gerald Commissiong, President and CEO of Todos Medical, added,
“After a thorough review of the immune-related COVID-19 testing
market, we believe that Aditxt’s platform technology represents a
unique multidimensional view of the immune system that will be
critical to allow physicians and scientists to categorize immune
responses to vaccines and therapeutic approaches for COVID-19 in
order to determine which interventions to use for which patients in
a personalized way. As vaccines for COVID-19 are rolled out, it is
imperative that we evaluate patients’ immune status prior to and
after vaccination, and track when immunity is gained and how long
it might last with repeat immune testing. The AditxtScore™ for
COVID-19 scoring system will initially include antibody and
neutralizing antibodies, and will soon include T-cell and B-cell
responses as well, which makes it the most comprehensive immune
profiling tool for COVID-19 available in the market.”
About Aditx Therapeutics
Aditxt is developing biotechnologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. The immune monitoring biotechnology is designed
to provide a personalized comprehensive profile of the immune
system. The immune reprogramming biotechnology is currently at the
pre-clinical stage and is designed to retrain the immune system to
induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com and
www.aditxtscore.com
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB:
TOMDF) engineers life-saving diagnostic solutions for the early
detection of a variety of cancers. The Company's state-of-the-art
and patented Todos Biochemical Infrared Analyses (TBIA) is a
proprietary cancer-screening technology using peripheral blood
analysis that deploys deep examination into cancer's influence on
the immune system, looking for biochemical changes in blood
mononuclear cells and plasma. For more information, please visit
https://www.todosmedical.com/.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product development; the
Company’s intellectual property position; the Company’s ability to
develop commercial functions; expectations regarding product launch
and revenue; the Company’s results of operations, cash needs,
spending, financial condition, liquidity, prospects, growth and
strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
entitled “Risk Factors” in the Company’s prospectus, dated
September 1, 2020, that was filed with the Securities and Exchange
Commission under File No. 333-248491, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company’s subsequent filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Aditxt Investor Relations:PCG AdvisoryJeff RamsonChief
Executive Officer646-863-6341IR@aditxt.com
Todos Investor Relations:Kim Sutton GolodetzLHA Investor
RelationsSenior Vice President(212) 838-3777kgolodetz@lhai.com
Todos Corporate Contact:Priyanka MisraTodos Medical(917)
983-4229 ext. 103priyanka@todosmedical.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024